EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com), a clinical stage biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, Monaco on May 19, 2008, 10:55 AM EDT (4:55 PM Central European Summer Time). Jack O’Reilly, NovaBay Senior Vice President of Corporate Development, will provide a corporate overview and update on the company. Presentation highlights are expected to include results from a recent Phase IIa clinical trial of NovaBay’s lead Aganocide compound for nasal decolonization of Staphylococcus aureus (including MRSA) to prevent surgical site infections, and from a Phase I study for a catheter and bladder lavage solution to prevent catheter associated urinary tract infections (CAUTI).
